Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Published 2011 View Full Article

Authors

Keywords

Journal

LANCET

Volume 378, Issue 9787, Pages 229-237

Publisher

Elsevier BV

Online

2011-07-23

DOI

10.1016/s0140-6736(11)60983-5

Ask authors/readers for more resources

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

LANCET

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Become a Peeref-certified reviewer

Ask a Question. Answer a Question.